Biogen deviates from neuroscience drugs with $800M acquisition
Biogen is expanding its portfolio outside of neuroscience, announcing Monday it is purchasing a British biotech firm focused on retinal disorders for $800 million.
Biogen (Nasdaq: BIIB) is acquiring clinical stage gene therapy company Nightstar Therapeutics (Nasdaq: NITE), which is developing treatments for multiple retinal disorders. Its lead candidate, a treatment for a rare hereditary eye disorder that leads to blindness, is currently being tested in a Ph ase 3 trial.
The deal is expected to…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Blindness | Brain | Gene Therapy | Genetics | Health Management | Mergers and Aquisitions | Neurology | Opthalmology | UK Health | Vitamin A